


PRODUCT INFORMATION



Gossypin

Item No. 34142

CAS Registry No.: 652-78-8
Formal Name: 2-(3,4-dihydroxyphenyl)-8-(β-D-glucopyranosyloxy)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Synonym: Gossypetin-8-O-glucoside
MF: C₂₁H₂₀O₁₃
FW: 480.4
Purity: ≥95%
UV/Vis.: λ_{max}: 262, 382 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Plant/*Hibiscus vitifolius*



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Gossypin is supplied as a solid. A stock solution may be made by dissolving the gossypin in the solvent of choice, which should be purged with an inert gas. Gossypin is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of gossypin in DMSO and DMF is approximately 25 and 30 mg/ml, respectively.

Gossypin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, gossypin should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Gossypin has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Gossypin is a flavonoid glycoside originally isolated from *H. vitifolius* that has diverse biological activities.¹⁻⁵ It inhibits RANKL-induced osteoclastogenesis in RAW 264.7 cells when used at a concentration of 5 μM.¹ Gossypin inhibits Aurora B kinase (IC₅₀ = 11.07 μM in a cell-free assay using the human enzyme), as well as Aurora A kinase and p90 ribosomal S6 kinase 2 (RSK2) at 20 μM.^{2,3} It induces cell cycle arrest at the G₂/M phase and apoptosis in HGC-27 gastric cancer cells.³ Gossypin decreases lactate dehydrogenase (LDH) release induced by the glutathione-depleting agent D,L-buthionine-(S,R)-sulfoximine (Item No. 23691) in primary rat cortical cells (IC₅₀ = 7.4 μg/ml).⁴ It reduces acetic acid-induced writhing in mice, an effect that can be reversed by the opioid antagonist naloxone, in a dose-dependent manner.⁵

References

1. Kunnumakkara, A.B., Nair, A.S., Ahn, K.S., et al. *Blood* **109**(12), 5112-5121 (2007).
2. Jung, Y., Shin, S.Y., Yong, Y., et al. *Chem. Biol. Drug Des.* **85**(5), 574-585 (2015).
3. Wang, L., Wang, X., Chen, H., et al. *Phytother. Res.* **33**(3), 640-650 (2019).
4. Yoon, I., Lee, K.H., and Cho, J. *Arch. Pharm. Res.* **27**(4), 454-459 (2004).
5. Viswanathan, S., Sambantham, P.T., Reddy, K., et al. *Eur. J. Pharmacol.* **98**(2), 289-291 (1984).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM